References
1. Grzeskowiak LE, Mol BW. Off-label prescribing in pregnancy-a case of risky business or business as usual? Eur J Obstet Gynecol Reprod Biol 2015; 187: 78-9.
2. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011; 157C: 175-82.
3. van der Graaf R, van der Zande ISE, den Ruijter HM, Oudijk MA, van Delden JJM, Oude Rengerink K, Groenwold RHH. Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach. Trials 2018; 19: 78.
4. Somers GS. Thalidomide and congenital abnormalities. Lancet 1962; 1: 912-3.
5. Troisi R, Hatch EE, Titus L. The Diethylstilbestrol Legacy: A Powerful Case Against Intervention in Uncomplicated Pregnancy. Pediatrics 2016; 138: S42-S44.
6. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas). Cancer 1970; 25: 745-57.
7. Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M. Designing drug trials: considerations for pregnant women. Clin Infect Dis 2014; 59 Suppl 7: S437-44.
8. Briggs GG, Freeman RK, Tower CV. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 12 Editon. Baltimore: Lippincott Williams & Wilkins (LWW), 2021.
9. Regulations UCoF. Protection of human subjects. 45 CFR 46, Subpart B. In, 2009.
10. Ances BM. New concerns about thalidomide. Obstet Gynecol 2002; 99: 125-8.
11. Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Womens Health Issues 2013; 23: e39-45.
12. Lyerly AD, Little MO, Faden R. The second wave: Toward responsible inclusion of pregnant women in research. Int J Fem Approaches Bioeth 2008; 1: 5-22.
13. Kazma JM, van den Anker J, Allegaert K, Dallmann A, Ahmadzia HK. Anatomical and physiological alterations of pregnancy. J Pharmacokinet Pharmacodyn 2020; 47: 271-85.
14. Torres-Vergara P, Escudero C, Penny J. Drug Transport at the Brain and Endothelial Dysfunction in Preeclampsia: Implications and Perspectives. Front Physiol 2018; 9: 1502.
15. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002; 100: 465-73.
16. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140-56.
17. Griffiths SK, Campbell JP. Placental structure, function and drug transfer. Bja Educ 2015; 15: 84-89.
18. Mirkin BL. Perinatal pharmacology: placental transfer, fetal localization, and neonatal disposition of drugs. Anesthesiology 1975; 43: 156-70.
19. Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 2000; 30: 243-48.
20. Desoye G, Hofmann HH, Weiss PAM. Insulin Binding to Trophoblast Plasma-Membranes and Placental Glycogen-Content in Well-Controlled Gestational Diabetic Women Treated with Diet or Insulin, in Well-Controlled Overt Diabetic-Patients and in Healthy Control Subjects. Diabetologia 1992; 35: 45-55.
21. Brownbill P, Sebire N, McGillick EV, Ellery S, Murthi P. Ex Vivo Dual Perfusion of the Human Placenta: Disease Simulation, Therapeutic Pharmacokinetics and Analysis of Off-Target Effects. Methods Mol Biol 2018; 1710: 173-89.
22. Devkota R, Khan GM, Alam K, Sapkota B, Devkota D. Impacts of counseling on knowledge, attitude and practice of medication use during pregnancy. BMC Pregnancy Childbirth 2017; 17: 131.
23. Kennedy DA, Lupattelli A, Koren G, Nordeng H. Herbal medicine use in pregnancy: results of a multinational study. BMC Complement Altern Med 2013; 13: 355.
24. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499-507.
25. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by counselling women on drug, chemical, and radiation exposure during the first trimester. Teratology 1990; 41: 657-61.
26. Henderson E, Mackillop L. Prescribing in pregnancy and during breast feeding: using principles in clinical practice. Postgrad Med J 2011; 87: 349-54.
27. Sun D, Hutson JR, Garcia-Bournissen F. Drug therapy during pregnancy. Br J Clin Pharmacol 2020.
28. Tomasulo P. LactMed-new NLM database on drugs and lactation. Med Ref Serv Q 2007; 26: 51-8.
29. Fitzpatrick RB. REPROTOX: an information system on environmental hazards to human reproduction and development. Med Ref Serv Q 2008; 27: 73-80.
30. Hayes DK, Robbins CL, Ko JY. Trends in Selected Chronic Conditions and Related Risk Factors Among Women of Reproductive Age: Behavioral Risk Factor Surveillance System, 2011-2017. J Womens Health (Larchmt) 2020; 29: 1576-85.
31. National Heart L, Blood I, National Asthma E, Prevention Program A, Pregnancy Working G. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol 2005; 115: 34-46.
32. Zetstra-van der Woude PA, Vroegop JS, Bos HJ, de Jong-van den Berg LT. A population analysis of prescriptions for asthma medications during pregnancy. J Allergy Clin Immunol 2013; 131: 711-7.
33. Murphy VE, Gibson PG. Asthma in pregnancy. Clin Chest Med 2011; 32: 93-110.
34. Fraser FC, Fainstat TD. Production of congenital defects in the off-spring of pregnant mice treated with cortisone; progress report. Pediatrics 1951; 8: 527-33.
35. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: A systematic review. J Clin Lipidol 2016; 10: 1081-90.
36. Adminstration FAD. FDA Drug Safety Communication. In, 2021.
37. Lateef A, Petri M. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 2013; 27: 435-47.
38. Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014; 20: 1091-8.
39. Rom AL, Wu CS, Olsen J, Kjaergaard H, Jawaheer D, Hetland ML, Vestergaard M, Morch LS. Fetal growth and preterm birth in children exposed to maternal or paternal rheumatoid arthritis: a nationwide cohort study. Arthritis Rheumatol 2014; 66: 3265-73.
40. Rubin R. Addressing Barriers to Inclusion of Pregnant Women in Clinical Trials. JAMA 2018; 320: 742-44.
41. Kaposy C. Presumptive Inclusion and Legitimate Exclusion Criteria. In: Clinical Research Involving Pregnant Women, edsBaylis F, Ballantyne A, Cham: Springer, 2016.
42. Payne P. Including Pregnant Women in Clinical Research: Practical Guidance for Institutional Review Boards. Ethics Hum Res 2019; 41: 35-40.
43. Administration. USFaD. Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials Guidance for Industry - Draft Guidance. In, 2018.
44. McCullough LB, Coverdale JH, Chervenak FA. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. Am J Obstet Gynecol 2005; 193: 901-7.
45. Taylor MM, Kobeissi L, Kim C, Amin A, Thorson AE, Bellare NB, Brizuela V, Bonet M, Kara E, Thwin SS, Kuganantham H, Ali M, Oladapo OT, Broutet N. Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action. Lancet Glob Health 2021; 9: e366-e71.
46. Gonzalez D, Boggess KA, Cohen-Wolkowiez M. Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy. Obstet Gynecol 2015; 125: 953-58.
47. Laughon MM, Benjamin DK, Jr., Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowiez M. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011; 4: 643-52.
48. Benjamin DK, Jr., Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 2006; 296: 1266-73.
49. De Sousa Mendes M, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, Bouazza N, Foissac F, Blanche S, Le MP, Peytavin G, Treluyer JM, Urien S, Benaboud S. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol 2016; 81: 646-57.
50. Zhang Z, Unadkat JD. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs. Drug Metab Dispos 2017; 45: 939-46.
51. Benaboud S, Treluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, Rey E, Pannier E, Firtion G, Launay O, Hirt D. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother 2012; 56: 776-82.
52. Alsaied T, Baskar S, Fares M, Alahdab F, Czosek RJ, Murad MH, Prokop LJ, Divanovic AA. First-Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2017; 6.
53. Fung HB, Kirschenbaum HL. Treatment regimens for patients with toxoplasmic encephalitis. Clin Ther 1996; 18: 1037-56; discussion 36.
54. Di Carlo R, Pagnini G, Pelagalli GV. Effect of amitriptyline and butriptyline on fetal development in rats. J Med 1971; 2: 271-5.
55. Beyer BK, Guram MS, Geber WF. Incidence and potentiation of external and internal fetal anomalies resulting from chlordiazepoxide and amitriptyline alone and in combination. Teratology 1984; 30: 39-45.
56. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606.
57. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-8.
58. Munk-Olsen T, Liu XQ, Viktorin A, Brown HK, Di Florio A, D’Onofrio BM, Gomes T, Howard LM, Khalifeh H, Krohn H, Larsson H, Lichtenstein P, Taylor CL, Van Kamp I, Wesseloo R, Meltzer-Brody S, Vigod SN, Bergink V. Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiat 2018; 5: 644-52.
59. Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, Erebara A, Einarson A, Ornoy A. Pregnancy Outcome Following In Utero Exposure to Lithium: A Prospective, Comparative, Observational Study. Am J Psychiat 2014; 171: 785-94.
60. Baldwin JA, Davidson EJ, Pritchard AL, Ridings JE. The reproductive toxicology of paroxetine. Acta Psychiatr Scand Suppl 1989; 350: 37-9.
61. Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet 1976; 2: 914-5.
62. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS, Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W, Michelfelder EC, Sr., Rempel GR, Silverman NH, Spray TL, Strasburger JF, Tworetzky W, Rychik J, American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Y, Council on Clinical Cardiology CoCS, Anesthesia, Council on C, Stroke N. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014; 129: 2183-242.
63. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978; 202: 436-8.
64. Bandoli G, Palmsten K, Smith CJF, Chambers CD. A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes. Rheum Dis Clin N Am 2017; 43: 489.
65. Harrod MJ, Sherrod PS. Warfarin embryopathy in siblings. Obstet Gynecol 1981; 57: 673-6.
66. Howe AM, Webster WS. The warfarin embryopathy: a rat model showing maxillonasal hypoplasia and other skeletal disturbances. Teratology 1992; 46: 379-90.
Table 1. The ten requirements for inclusion of pregnant women in clinical trials outlined by the FDA [43]